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THE HYPOXIC CELL RADIOSENSITIZER mis-
onidazole (1 - (2 -nitroimidazol - 1 -yl) - 3 -
methoxypropan-2-ol; Ro 07-0582, Roche
Laboratories; NSC 261037; MISO) is cur-
rently undergoing clinical trial ofits value
in the radiotherapy of tumours in several
sites, including cerebral gliomas. Patients
with brain tumours frequently require
anticonvulsants as part of their general
medical care, and phenytoin and pheno-
barbitone are commonly used.
Previous studies from this laboratory
have shownthatpretreatment withpheny-
toin or phenobarbitone shortens the half-
life of MISO in mice and dogs through
induction of hepatic drug-metabolizing
enzymes, which increase the rate ofoxida-
tive demethylation of MISO to desmethyl-
misonidazole (1-(2-nitroimidazol-1-yl)-2,3-
propandiol; Ro 05-9963, Roche Labora-
tories; NSC 261036; DEMIS) (Workman,
1979; White & Workman, 1979). In addi-
tion, pretreatment with these agents
significantlyreducesthe acutelethaleffects
ofMISO in mice (Workman, 1980).
In this paper we describe the results
of a preliminary study designed to in-
vestigate the effects of phenytoin on the
plasma pharmacokinetics ofMISO in man.
Six patients with advanced malignancy
of various types and with cerebral meta-
stases received MISO (Roche, 3 g/m2 p.o.)
before and after a 14-day course ofpheny-
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toin (5,5-diphenylhydantoin; Epanutin,
Parke Davis; 100 mg p.o. t.d.s.). Six other
patients, 3 with cerebral metastases, were
similarly assessed as controls without
phenytoin administration. There were no
additional changes in drug regime during
the study which would be likely to in-
fluence MISO metabolism. All patients
gave full informed consent.
Blood samples were taken by venipunc-
tureimmediately beforeMISO administra-
tion and at various times after, usually 2,
1, 2, 4, 8, 12, 24 and 30 h. Plasma concen-
trations ofMISO and DEMIS were deter-
mined by reverse-phase high-performance
liquid chromatography (HPLC) (Work-
man et al., 1978a). Pharmacokinetic para-
meters were calculated as described pre-
viously (Workman et al., 1978b; Work-
man, 1979). Statistical analysis was by
Student's t test.
The pertinent pharmacokinetic data are
summarized in Table I. Comparison ofthe
data obtained on the first MISO dose re-
vealed no significant differences between
the control and phenytoin groups for any
of the kinetic parameters (P> 0 1). This
indicated that the pharmacokinetics of
MISO wereinitiallyverysimilarforthetwo
groups.
Forthe control group, comparison ofthe
dataforthe first and second doses ofMISO
showed that the percentage change for
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TABLE I.-Pharmacokinetic parameters (mean +s.d_, n= 6 per group)
Misonidazole
ti (h) Peak cone. (mM) AUC (0-
1st 2nd 1st 2nd 1st
Dose Dose Dose Dose Dose
Control 13-2+5-1 12-7+3 9 0-48+0411 0 49+0-13 10 1+4-8
Phenytoin 11-1+3-7 7-5+1-4 0-60+0-23 0-56+0-12 10-1+3-2
each of the kinetic parameters was not
significantly different from zero (P > 0 1).
Thus the pharmacokinetics of MISO were
not altered by the previous administration
of the drug. In contrast, a similar com-
parison for the phenytoin group data
revealed a number of differences between
the two doses, which could therefore be
attributed to the phenytoin administra-
tion.
The half-life of MISO was considerably
shortened (mean reduction 31 + 9%, s.d.,
P < 0.001) (Table I). This effect was seen
for all 6 patients, but was more marked in
those with longer initial half-lives. The
area under the curve (AUC) of plasma
MISO concentration against time was also
reduced by a similar amount (mean reduc-
tion 29+14%, s.d., 0-01>P>0.001)
(Table I). In contrast, the peak plasma
concentration for the metabolite DEMIS
was markedly increased (mean increase
75 + 16%, s.d., P < 0-001) (Table I) as was
the AUC (69 + 49%, s.d., 0-05 >P > 0*02)
(data not shown). However, neither the
peak plasma MISO concentration (Table I)
nor the plasma concentration 4 h after
administration of the drug (time of irra-
diation) (Table II) was affected by pheny-
toin (P > 0.1). In 4/6 patients the AUC for
total plasma 2-nitroimidazole (MISO +
DEMIS) was reduced after phenytoin ad-
TABLE II.-Plasma misonidazole concen-
trations 4 h after drug administration
(mean + s.d., n= 6 per group)
Plasma misonidazole (mM)
at 4 h
1st dose 2nd dose
Control 0-40+ 0-08 0-41+0l10
Phenytoin 0-58 + 0-25 0O53 + 0-15
0oo
Desmethyl misonidazole
)) (mM.h) Peak conc. (mM)
2nd 1st 2nd
Dose Dose Dose
9*9+5-3 0.056+0.016 0-052+0 009
6-8+1-3 0-058 + 0-018 0 100+ 0.030
ministration, but this was not significant
for the whole group (P> 0 1).
The above data clearly indicate a
marked effect of a short course of pheny-
toinonthepharmacokinetics ofMISO. The
shortened half-life and reduced AUC for
plasma MISO were associated with a con-
comitant increase in the concentrations of
oxidative metaboliteDEMIS. Theseeffects
are similar to our recent observations with
both phenytoin and phenobarbitone in
mice and dogs (Workman, 1979; White &
Workman, 1980).
Phenytoin is known to increase the rate
of elimination of many drugs, in experi-
mental animals and in man, by acting as a
potent inducer of hepatic microsomal
drug-metabolizing enzymes (Conney, 1967;
Pirttiaho et al., 1978). Our data indicate
that such induction increases the rate of
oxidative demethylation of MISO to DE-
MIS.
Clinical doses of MISO are limited by
its neurotoxicity, particularly peripheral
neuropathy, and atotaldose not exceeding
12 g/m2 is now recommended (Dische
et al., 1977; Urtasun et al., 1978). More-
over, there is evidence that the incidence
of neuropathy is related to the plasma
AUC for MISO, and dose adjustment on
the basis of plasma pharmacokinetics has
been advocated (Saunders et al., 1978). It
therefore appears possible that patients
exposed to potent hepatic enzyme-induc-
ing agents, such as phenytoin and pheno-
barbitone, may be protected to some
extent from neurotoxicity by rapid drug
clearance. It has not yet been determined,
however, whether there is any correlation
between phenytoin or phenobarbitone
administration and the clinical incidence
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or severity ofMISO neurotoxicity. Astudy
on these lines is in progress.
We should also consider the possible
effects of phenytoin on the therapeutic
action of MISO. The degree of radiosensi-
tization is a function oftumour MISO con-
centrationduringirradiation(McNallyetal.,
1978) and this is closely related to plasma
concentration (Dische et at., 1977; Ash
et al., 1979). Current clinical practice is to
irradiate 4 h after MISO administration,
and we have shown that neither the peak
plasma MISO concentration nor the 4 h
concentration is affected by phenytoin.
In addition, we have previously shown
thatpeaktumourMISO concentrations are
not altered in mice pretreated with
phenytoin or phenobarbitone (Workman,
1979). We therefore feel it is unlikely that
phenytoin administration would affect the
radiosensitization of tumour cells by
MISO. MISO also exhibits selective cyto-
toxicity towards hypoxic cells (Hall &
Roizin-Towle, 1975; Stratford & Adams,
1978). However, its clinical significance
and the effects of enzyme induction on
that are unknown.
In conclusion, phenytoin, and possibly
other potent liver enzyme-inducing agents
such as phenobarbitone, may reduce the
incidence of dose-limiting neurotoxicity
of MISO without compromising the direct
tumour radiosensitization by the drug.
The possible effects on the drug's anti-
tumour cytotoxicity are uncertain.
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